The Weekly Notable Startup Funding Report takes us on a trip across various ecosystems in the US, highlighting some of the notable funding activity in the various markets that we track. The notable startup funding rounds for the week ending 8/14/21 featuring funding details for Gusto, FalconX, and twenty-five other rounds that you need to […]
Microbiome science can explain how genetics and the body interact, explaining why similar genes can generate variable outcomes among populations. Understanding these interactions introduces new pathways for treatment and prevention of disease and ailments, ultimately extending health and life spans. Evvy is a newly-launched startup focused on using metagenomic sequencing to understand women’s health like never before. The company’s first product is an at-home vaginal microbiome test that’s used to assess and understand vaginal health to address conditions such as yeast infections, UTIs, infertility, gynecologic cancers, STIs, and premature birth. The test is approved for use in all states and is available direct-to-consumer on Evvy’s website as well as through clinical partners. Evvy plans to expand its biomarker offering to include different conditions so that women are empowered to take control of their health with data and scientific knowledge that was previously unattainable. AlleyWatch caught up with CEO and Cofounder Priyanka Jain to learn more about how Evvy is disrupting women’s health, the company’s strategic plans, recent round of funding from investors that include General Catalyst, BoxGroup, Virtue, Human Ventures, and G9 Ventures, BBG Ventures.